Liset Pengel
Overview
Explore the profile of Liset Pengel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaza G, Cucchiari D, Becker J, de Vries A, Eccher A, Florquin S, et al.
Transpl Int
. 2023 Jul;
36:11410.
PMID: 37470063
The ESOT TLJ 3.0. consensus conference brought together leading experts in transplantation to develop evidence-based guidance on the standardization and clinical utility of pre-implantation kidney biopsy in the assessment of...
2.
Cillo U, Weissenbacher A, Pengel L, Jochmans I, Roppolo D, Amarelli C, et al.
Transpl Int
. 2022 Nov;
35:10915.
PMID: 36406781
The European Society for Organ Transplantation (ESOT) has created a platform for the development of rigorous and regularly updated evidence based guidelines for clinical practice in the transplantation field. A...
3.
De Smet S, ODonoghue K, Lormans M, Monbaliu D, Pengel L
Transplantation
. 2022 Oct;
107(1):e11-e26.
PMID: 36192838
Background: The impaired physical fitness of end-stage liver disease patients often persists after liver transplantation (LT) and compromises posttransplant recovery. This systematic review and meta-analysis evaluated evidence supporting the potential...
4.
Mamode N, Bestard O, Claas F, Furian L, Griffin S, Legendre C, et al.
Transpl Int
. 2022 Aug;
35:10511.
PMID: 36033645
This guideline, from a European Society of Organ Transplantation (ESOT) working group, concerns the management of kidney transplant patients with HLA antibodies. Sensitization should be defined using a virtual parameter...
5.
Naesens M, Loupy A, Hilbrands L, Oberbauer R, Bellini M, Glotz D, et al.
Transpl Int
. 2022 Jun;
35:10137.
PMID: 35669977
Conditional marketing authorization (CMA) facilitates timely access to new drugs for illnesses with unmet clinical needs, such as late graft failure after kidney transplantation. Late graft failure remains a serious,...
6.
Hilbrands L, Budde K, Bellini M, Diekmann F, Furian L, Grinyo J, et al.
Transpl Int
. 2022 Jun;
35:10139.
PMID: 35669976
Clinical study endpoints that assess the efficacy of interventions in patients with chronic renal insufficiency can be adopted for use in kidney transplantation trials, given the pathophysiological similarities between both...
7.
Seron D, Rabant M, Becker J, Roufosse C, Bellini M, Bohmig G, et al.
Transpl Int
. 2022 Jun;
35:10135.
PMID: 35669975
The diagnosis of acute T cell-mediated rejection (aTCMR) after kidney transplantation has considerable relevance for research purposes. Its definition is primarily based on tubulointerstitial inflammation and has changed little over...
8.
Naesens M, Budde K, Hilbrands L, Oberbauer R, Bellini M, Glotz D, et al.
Transpl Int
. 2022 Jun;
35:10136.
PMID: 35669974
In kidney transplant recipients, late graft failure is often multifactorial. In addition, primary endpoints in kidney transplantation studies seek to demonstrate the short-term efficacy and safety of clinical interventions. Although...
9.
Roufosse C, Becker J, Rabant M, Seron D, Bellini M, Bohmig G, et al.
Transpl Int
. 2022 Jun;
35:10140.
PMID: 35669973
Antibody-mediated rejection (AMR) is caused by antibodies that recognize donor human leukocyte antigen (HLA) or other targets. As knowledge of AMR pathophysiology has increased, a combination of factors is necessary...
10.
Bestard O, Thaunat O, Bellini M, Bohmig G, Budde K, Claas F, et al.
Transpl Int
. 2022 Jun;
35:10138.
PMID: 35669972
Different types of kidney transplantations are performed worldwide, including biologically diverse donor/recipient combinations, which entail distinct patient/graft outcomes. Thus, proper immunological and non-immunological risk stratification should be considered, especially for...